TIMP1 and astrocytoma (excluding glioblastoma): The aim of this study was to assess the prognostic impact of CD63 alone and in combination with TIMP-1 by performing immunohistochemistry on a cohort of 111 astrocytomas,  described and used previously for evaluation of the prognostic potential of TIMP-1 [14].